At least three large pharmaceutical and biotechnology companies support the US Food and Drug Administration’s plan for regulating predictive laboratory-developed tests, but they also asked the agency to clarify how it would regulate the tests, according to publicly available comments on the
draft guidance.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.